|
|
 | | | |
- close
- close
- close
- close
| |||||||||
This excerpt taken from the ELN 20-F filed Feb 26, 2009. Tysabri-U.S.
In the U.S. market, we recorded net sales of
$421.6 million (2007: $217.4 million; 2006:
$28.2 million). Almost all of these sales are in relation
to the MS indication.
As of the end of December 2008, approximately
20,200 patients were on commercial therapy, which
represents an increase of 57% since the end of December 2007.
On January 14, 2008, the FDA approved the sBLA for
Tysabri for the treatment of patients with CD, and
Tysabri was launched in this indication at the end of the
first quarter of 2008. On December 12, 2008, we announced a
realignment of our commercial activities in Tysabri for
CD, shifting our efforts from a traditional sales model to a
model based on clinical support and education.
|
| |||||||
